All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.